A Phase 1 Randomized, Observer-Blinded,Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus F Protein Particle Vaccine in Healthy Adults.

Trial Profile

A Phase 1 Randomized, Observer-Blinded,Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus F Protein Particle Vaccine in Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs RSV F protein vaccine-Novavax (Primary) ; Aluminium phosphate
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Sponsors Novavax
  • Most Recent Events

    • 06 Dec 2012 Results have been published in Vaccine according to a Novavax media release. Results were also summarised in the media release.
    • 27 Sep 2012 Results will be presented at the 8th Annual International Respiratory Virus Symposium (RSV 2012), according to a Novavax media release.
    • 22 Mar 2012 Results will be presented at the XIV International Symposium on Respiratory Viral Infections, according to a Novavax media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top